• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Evommune Inc.

    3/5/26 4:14:38 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVMN alert in real time by email
    S-8 1 evmn-20260305.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 5, 2026

    Registration No. 333-   

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Evommune, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    85-0742575

    (State or Other Jurisdiction

    of Incorporation)

     

    (IRS Employer

    Identification No.)

     

     

     

    1841 Page Mill Road, Suite 100

    Palo Alto, CA

    94304

    (Address of Principal Executive Offices)

    (Zip Code)

     

    Evommune, Inc. 2025 Equity Incentive Plan

    (Full titles of the plans)

    Luis Peña

    Chief Executive Officer

    Evommune, Inc. 1841 Page Mill Road, Suite 100

    Palo Alto, CA 94304

    Tel: (925) 247-4481

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    Eric Blanchard

    Minkyu Park

    Cooley LLP

    500 Boylston Street, 14th Floor

    Boston, MA 02116

    Tel: (617) 937-2300

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large Accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


    Explanatory Note

    Evommune, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering 1,576,204 shares of the Registrant’s common stock, par value $0.0001 (the “Common Stock”), issuable to eligible persons under the Registrant’s 2025 Equity Incentive Plan (the “2025 Plan”), which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s Form S-8 filed with the Commission on November 7, 2025 (File No. 333-291386) (the “Prior Registration Statement”). The additional shares of Common Stock under the 2025 Plan have become reserved for issuance as a result of the operation of the “evergreen” provisions in the 2025 Plan, which provide that the total number of shares subject to such plan will be increased on the first day of each calendar year pursuant to a specified formula.

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statement relate and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statement, to the extent relating to the registration of Common Stock issuable under the 2025 Plan, are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”) and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.

    Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

    (a) the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Commission on March 5, 2026;

    (b) the Registrant’s Current Report on Form 8-K filed with the SEC on February 13, 2026; and

    (c) The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed on November 4, 2025 (File No. 001-42938) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 5, 2026.

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

    Item 4.

    Description of Securities.

    Not applicable.


    Item 5.

    Interests of Named Experts and Counsel.

    Not applicable.

    Item 6.

    Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant’s amended and restated certificate of incorporation permits indemnification of its directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant’s amended and restated bylaws provide that the Registrant will indemnify its directors and executive officers and permit it to indemnify its other officers, employees, and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law.

    The Registrant has entered into indemnification agreements with its directors and executive officers, whereby it has agreed to indemnify its directors and executive officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or executive officer was, or is threatened to be made, a party by reason of the fact that such director or executive officer is or was a director, executive officer, employee or agent of the Registrant, provided that such director or executive officer acted in good faith and in a manner that the director or executive officer reasonably believed to be in, or not opposed to, the best interest of the Registrant. At present, there is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.

    The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act, that might be incurred by any director or officer in his capacity as such.

    Item 7.

    Exemption from Registration Claimed.

    Not applicable.


     

    Item 8.

    Exhibits.

    The exhibits to this Registration Statement are listed below:

     

     

     

    Exhibit
    Number

    Description

     

     

     4.1

    Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-42938), filed with the Commission on November 7, 2025).

     

     

     4.2

    Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated herein by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-290793), filed with the Commission on October 9, 2025).

     

     

     4.3

    Form of Common Stock Certificate of the Registrant (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-290793), filed with the Commission on October 9, 2025).

     

     

     5.1*

    Opinion of Cooley LLP.

     

     

    23.1*

    Consent of BDO USA, P.C., Independent Registered Public Accounting Firm.

     

     

    23.2*

    Consent of Cooley LLP (included in Exhibit 5.1).

     

     

    24.1*

    Power of Attorney (included on the signature page).

     

     

    99.1

    Evommune, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registrant's Registration Statement on Form S-8 (File No. 333-291386), filed with the Commission on November 7, 2026).

     

     

    99.2

    Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise, Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice under the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.3(b) to the Registrant’s Registration Statement on Form S-1/A (File No. 333-290793), filed with the Commission on October 17, 2025).

     

     

     

     

    107*

    Filing Fee Table.

    * Filed herewith

     


    Item 9.

    Undertakings.

    (a)

    The undersigned Registrant hereby undertakes:

    (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

    (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b)

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, California, on March 5, 2026.

     

    Evommune, Inc.

    Date: March 5, 2026

    By:

    /s/ Luis Peña

    Luis Peña

    President and Chief Executive Officer

     

     

     

    (Principal Executive Officer)

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Luis Peña and Kyle Carver and each of them, as his or her true and lawful attorney-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name

    Title

    Date

    /s/ Luis Peña

    President, Chief Executive Officer and Director

    March 5, 2026

    Luis Peña

    (Principal Executive Officer)

    /s/ Kyle Carver

    Chief Financial Officer

    March 5, 2026

    Kyle Carver, CPA, MBA

    (Principal Financial and Accounting Officer)

    /s/ Benjamin F. McGraw

    Chairman

    March 5, 2026

    Benjamin F. McGraw, III, Pharm.D.

    /s/ Eugene A. Bauer

    Director

    March 5, 2026

    Eugene A. Bauer, M.D.

    /s/ David E. Cohen

    Director

    March 5, 2026

    David E. Cohen, M.D., M.P.H.

    /s/ Derek DiRocco

    Director

    March 5, 2026

    Derek DiRocco, Ph.D.

    /s/ Arthur Kirsch

    Director

    March 5, 2026

    Arthur Kirsch

    /s/ Rob Hopfner

    Director

    March 5, 2026

    Rob Hopfner, R.Ph., Ph.D.

    /s/ Felice Verduyn-van Weegen

    Director

    March 5, 2026

    Felice Verduyn-van Weegen

     

     


    Get the next $EVMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVMN

    DatePrice TargetRatingAnalyst
    4/7/2026$50.00Outperform
    Oppenheimer
    1/22/2026$42.00Outperform
    Oppenheimer
    1/8/2026$40.00Strong Buy
    Raymond James
    1/6/2026$35.00Buy
    H.C. Wainwright
    12/1/2025$42.00Outperform
    Leerink Partners
    12/1/2025$36.00Overweight
    Morgan Stanley
    12/1/2025Outperform
    William Blair
    12/1/2025$40.00Outperform
    Evercore ISI
    More analyst ratings

    $EVMN
    SEC Filings

    View All

    SEC Form 424B3 filed by Evommune Inc.

    424B3 - Evommune, Inc. (0002044725) (Filer)

    4/24/26 4:23:45 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Evommune Inc.

    DEFA14A - Evommune, Inc. (0002044725) (Filer)

    4/21/26 4:06:29 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Evommune Inc.

    DEF 14A - Evommune, Inc. (0002044725) (Filer)

    4/21/26 4:05:36 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hopfner Robert Lorne bought $17,350 worth of shares (1,000 units at $17.35) (SEC Form 4)

    4 - Evommune, Inc. (0002044725) (Issuer)

    12/22/25 7:07:35 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

    Company to showcase expansion opportunity for EVO756 (MRGPRX2 Antagonist) into third indication of migraine prophylaxis; Phase 2b study to initiate in 3Q26 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday, April 13, 2026, at 11:00 a.m. PT (2:00 p.m. ET). The event will include presentations from members of Evommune's management team and the following two leading experts in migraine: Stewart

    4/6/26 9:00:00 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    – Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26 and 2H26, respectively – Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend runway through 2028 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

    3/5/26 4:01:00 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evommune Announces $125 Million Private Placement

    Evommune, Inc. ("Evommune" or the "Company") (NYSE:EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $27.88. Evommune anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any transaction-related expenses. The private placement is expected to close on or about Feb

    2/12/26 8:30:00 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Patel Jeegar Pravinkumar

    4 - Evommune, Inc. (0002044725) (Issuer)

    4/17/26 5:24:42 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Drew Janice Suzann

    4 - Evommune, Inc. (0002044725) (Issuer)

    4/17/26 5:24:26 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bauer Eugene

    4 - Evommune, Inc. (0002044725) (Issuer)

    4/17/26 5:23:59 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Evommune with a new price target

    Oppenheimer resumed coverage of Evommune with a rating of Outperform and set a new price target of $50.00

    4/7/26 8:50:59 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Evommune with a new price target

    Oppenheimer initiated coverage of Evommune with a rating of Outperform and set a new price target of $42.00

    1/22/26 8:46:17 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Evommune with a new price target

    Raymond James initiated coverage of Evommune with a rating of Strong Buy and set a new price target of $40.00

    1/8/26 8:54:08 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Financials

    Live finance-specific insights

    View All

    Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

    - Trial met primary efficacy endpoint at week 12 - EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo - 33% placebo-adjusted improvement in EASI at week 12 - 23% of EVO301 patients achieved IGA 0/1 at week 12 - Company to hold conference call and webcast at 8:30 a.m. ET today Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of

    2/10/26 7:30:00 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care